Troy Wilson is a successful, serial entrepreneur. His passion is to build exceptional companies that create significant value for employees, investors and, most importantly, patients. He is a co-founder of Kura Oncology, Inc., and he has served as President and Chief Executive Officer and as a member of the board of directors since August 2014. Previously, Dr. Wilson served as President and Chief Executive Officer of Wellspring Biosciences, Inc., a privately-held biopharmaceutical company, and its parent company Araxes Pharma LLC from July 2012 to March 2019 and as President and Chief Executive Officer of Avidity Biosciences LLC, a privately-held biopharmaceutical company, from November 2012 to February 2019. Dr. Wilson served as the President and Chief Executive Officer and a member of the Board of Directors of Intellikine, Inc., a privately-held biopharmaceutical company, from April 2007 to January 2012 and from August 2007 to January 2012, respectively, until its acquisition by Takeda Pharmaceutical Company Limited. He has also been a member of the board of directors of Puma Biotechnology, Inc., a publicly-held biopharmaceutical company, since October 2013, Chairman and a member of the board of directors of Avidity Biosciences, Inc. since February 2019 and November 2012, respectively, and a member of the board of managers of Araxes Pharma LLC since July 2012. Dr. Wilson holds a JD from New York University and graduated with a PhD in bioorganic chemistry and a BA in biophysics from the University of California, Berkeley.